Sandbox:skorjian2: Difference between revisions
Jump to navigation
Jump to search
Sergekorjian (talk | contribs) No edit summary |
Sergekorjian (talk | contribs) No edit summary |
||
Line 1: | Line 1: | ||
'''Adjuvant therapy''' | |||
# Interferon alfa-2a (Roferon-A) | # Interferon alfa-2a (Roferon-A) | ||
# Interferon alfa-2b (Intron-A) | # Interferon alfa-2b (Intron-A) | ||
# Peginterferon alfa-2b (Sylatron) | # Peginterferon alfa-2b (Sylatron) | ||
'''Metastatic or unresectable disease''' | |||
:* | :* ''Single Agent Chemotherapy'' | ||
::# Dabrafenib (Tafinlar) | ::# Dabrafenib (Tafinlar) | ||
::# Dacarbazine (DTIC) | ::# Dacarbazine (DTIC) | ||
Line 20: | Line 20: | ||
::# Vemurafenib (Zelboraf) | ::# Vemurafenib (Zelboraf) | ||
:* | :* ''Combination Chemotherapy'' | ||
::# Paclitaxel nanoparticle albumin-bound + Bevacizumab + Carboplatin (ABC) | ::# Paclitaxel nanoparticle albumin-bound + Bevacizumab + Carboplatin (ABC) | ||
::# Carboplatin + Paclitaxel (CP) | ::# Carboplatin + Paclitaxel (CP) |
Revision as of 01:22, 22 August 2015
Adjuvant therapy
- Interferon alfa-2a (Roferon-A)
- Interferon alfa-2b (Intron-A)
- Peginterferon alfa-2b (Sylatron)
Metastatic or unresectable disease
- Single Agent Chemotherapy
- Dabrafenib (Tafinlar)
- Dacarbazine (DTIC)
- Docetaxel (Taxotere)
- High-dose (HD) IL-2
- IL-2 maintenance biotherapy
- Imatinib (Gleevec)
- Ipilimumab (Yervoy)
- Nivolumab (Opdivo)
- Paclitaxel (Taxol)
- Pembrolizumab (Keytruda)
- Temozolomide (Temodar)
- Trametinib (Mekinist)
- Vemurafenib (Zelboraf)
- Combination Chemotherapy
- Paclitaxel nanoparticle albumin-bound + Bevacizumab + Carboplatin (ABC)
- Carboplatin + Paclitaxel (CP)
- Carboplatin + Paclitaxel + nanoparticle albumin-bound
- Carboplatin + Paclitaxe +, Sorafenib
- Cisplatin + Dacarbazine ± Carmustine
- Cisplatin + Dacarbazine + IL-2 + IFN alfa-2b ± Carmustine
- Cisplatin + Paclitaxel + Dacarbazine
- Cisplatin + Vinblastine + Dacarbazine (CVD)
- CVD + IL-2 + IFN alfa-2b (sequential biochemotherapy)
- Temozolomide + Bevacizumab (TB)
- Dabrafenib + Trametinib
- Ipilimumab + Dacarbazine
- Ipilimumab + Nivolumab